Prognostic value of KRAS exon 2 gene mutations in stage III colon cancer: Post hoc analyses of the PETACC8 trial.
Julien Taïeb
Honoraria - Merck Serono; Sanofi
Jean-François Emile
No relevant relationships to disclose
Karine Le Malicot
No relevant relationships to disclose
Aziz Zaanan
No relevant relationships to disclose
Josep Tabernero
Consultant or Advisory Role - Merck Serono; Sanofi
Honoraria - Merck Serono; Sanofi
Enrico Mini
No relevant relationships to disclose
Philippe Rougier
Consultant or Advisory Role - Merck Serono; Sanofi
Jean Luc VAN Laethem
No relevant relationships to disclose
John A. Bridgewater
Consultant or Advisory Role - Merck Serono; Sanofi
Gunnar Folprecht
Honoraria - Merck Serono
Ramon Salazar
Honoraria - Merck Serono
Ayman Zawadi
No relevant relationships to disclose
Eric Van Cutsem
No relevant relationships to disclose
Come Lepage
No relevant relationships to disclose
Pierre Laurent-Puig
Honoraria - Merck Serono
Helene Blons
No relevant relationships to disclose